CCDC72 Activators
CCDC72 Activators comprise an array of chemical compounds that indirectly promote the functionality of CCDC72 through distinct cellular signaling routes. This group includes Forskolin, which by stimulating adenylate cyclase, elevates intracellular cAMP levels, indirectly fostering CCDC72 activity via PKA-dependent phosphorylation processes that may involve proteins interacting with CCDC72. Another cAMP pathway modulator, Dibutyryl cAMP, mimics the natural secondary messenger to activate PKA and may enhance CCDC72's role within its associated signaling networks. The PDE inhibitors, IBMX and Sildenafil, raise cAMP and cGMP concentrations, respectively, potentially amplifying CCDC72 activity by empowering PKA or PKG to phosphorylate substrates that could be in CCDC72's sphere of influence. Furthermore, Y-27632 might augment CCDC72 activity by modulating the actin cytoskeleton and related signaling, while PMA, by activating PKC, could bolster CCDC72 through phosphorylation of associated substrates.
The cellular influence of CCDC72 is also shaped by compounds that adjust various other signaling pathways. LY294002, by inhibiting PI3K, and U0126, by blocking MEK, may enrich CCDC72's function by tweaking AKT and MAPK/ERK pathways, respectively, which are likely to intersect with CCDC72's operational pathways.CCDC72 Activators encompass a selection of chemical compounds that indirectly bolster the functional activity of CCDC72 through distinct cellular signaling pathways. Forskolin and Dibutyryl cAMP, by increasing intracellular cAMP levels, activate PKA, which may indirectly enhance the activity of CCDC72 through phosphorylation of associated proteins within the cellular pathways CCDC72 is involved in. Similarly, IBMX and Sildenafil elevate cAMP and cGMP levels, which could potentiate CCDC72 function by activating PKA or PKG that might phosphorylate proteins in CCDC72's signaling network. Additionally, Y-27632 disrupts Rho kinase activity, potentially influencing CCDC72's role in actin cytoskeleton dynamics, while PMA activates PKC, possibly enhancing CCDC72 activity via phosphorylation of interacting substrates.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective phosphodiesterase inhibitor, leading to increased cAMP and cGMP levels, which could enhance CCDC72 activity by potentiating PKA or PKG pathways, potentially impacting proteins interacting with CCDC72. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Dibutyryl cAMP is a cAMP analog that activates PKA. Activated PKA may indirectly increase CCDC72 activity through phosphorylation of proteins within CCDC72-related signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a Rho-associated protein kinase inhibitor that could enhance CCDC72 activity by altering cytoskeletal dynamics, which may influence cellular processes where CCDC72 is involved. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which could enhance CCDC72 activity through phosphorylation of substrates that interact with or regulate CCDC72 in cellular signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may increase CCDC72 activity by altering downstream AKT signaling, potentially affecting CCDC72 interactions or function in related pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which could enhance CCDC72 activity by modifying the MAPK/ERK pathway, potentially impacting cellular processes associated with CCDC72. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis and could augment CCDC72 activity by activating calcium-dependent signaling pathways that might intersect with CCDC72's functional mechanisms. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor, which might enhance CCDC72 activity by reducing competitive phosphorylation events, thus favoring CCDC72-related signaling cascades. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate is a catechin known to inhibit several kinases, which may enhance CCDC72 activity by modulating signaling pathways that intersect with CCDC72's functional role. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore, which can increase intracellular calcium levels, thereby potentially enhancing CCDC72 activity by stimulating calcium-dependent proteins and pathways in which CCDC72 might be involved. | ||||||